Molnupiravir para el tratamiento de la COVID-19. Información para profesionales de la salud
Date
2022Document Number
OPS/HSS/MT/COVID-19/22-0021
Metadata
Show full item recordOther Language Versions
Abstract
La Organización Panamericana de la Salud presenta esta ficha informativa con recomendaciones sobre el uso del molnupiravir dirigidas a los profesionales de la salud. El molnupiravir es un profármaco que inhibe de manera significativa la replicación del SARS-CoV-2. Se emplea para el tratamiento de la COVID-19 leve y moderada en pacientes que presenten un riesgo alto de complicaciones, y ha demostrado una reducción considerable en la tasa de hospitalización o muerte de los pacientes con COVID-19.
Subject
Collections
This notice should be preserved along with the article's original URL.Attribution-NonCommercial-ShareAlike 3.0 IGO
Related items
Showing items related by title, author, creator and subject.
-
Organización Panamericana de la Salud; Health Systems and Services (HSS) (OPSUnited StatesWashington, D.C., 2022)La Organización Panamericana de la Salud presenta esta ficha informativa con recomendaciones sobre el uso del molnupiravir dirigidas a los profesionales de la salud. El molnupiravir es un profármaco que inhibe de manera ...
-
Pan American Health Organization; Health Systems and Services (HSS) (PAHOUnited StatesWashington, D.C., 2022)The Pan American Health Organization presents this information sheet with recommendations on the use of molnupiravir addressed to health professionals. Molnupiravir is a prodrug that significantly inhibits SARS-CoV-2 ...
-
Pan American Health Organization; Health Systems and Services (HSS) (PAHOUnited StatesWashington, D.C., 2022)The Pan American Health Organization presents this information sheet with recommendations on the use of molnupiravir addressed to patients. Molnupiravir is a prodrug that significantly inhibits SARS-CoV-2 replication. It ...